Agape ATP Corp.

ATPC

Nasdaq; healthcare; SIC 8000, Services-Health Services; CIK 0001713210

B

second fifth of 367 graded peers in healthcare

rank 105 of 367; percentile 28.4; sampling error 2.5 points; lower is stronger

A B C D E

B, the elk



Scoreboard	
Profitability	D/E percentile 81.2
Solvency	A percentile 8.9
Growth and financing	B percentile 32.5
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $24.6M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	late filer not computable: short runway, distress, fortress balance sheet
Inputs computable	8 of 14
Graded from	filings received through Apr 13, 2026 216 days before the rescan; latest periodic filing 10-Q received Aug 14, 2026
Last close	$1.39 2026-11-12; market equity $1.4M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Apr 13, 2026

ATP Corporation, a Nevada corporation ("the Company") was incorporated under the laws of the State of Nevada on June 1, 2016. ATP Corporation operates through its subsidiaries, namely, Agape ATP Corporation ("AATP LB"), a company incorporated in Labuan, Malaysia, and Agape Superior Living Sdn. Bhd. ("ASL"), a company incorporated in Malaysia on August 8, 2003. LB is an investment holding company with 100% equity interest in Agape ATP International Holding Limited ("AATP HK"), a company May 8, 2020, the Company entered into a Share Exchange Agreement with Mr.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 81.2						
Gross profitability	3.4%	32.3%		87.4	365	2025-12-31
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	1.0%	(6.6%)	82.8	799	2025-12-31
Gross margin stability, five years	5.7 pts	2.8 pts	73.4	242	2025-12-31
Solvency, sleeve percentile 8.9					
Twelve-month failure probability	not computable	0.08%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	14.37	(0.31)	5.0	743	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	11.82x	2.96x	12.7	825	2025-12-31
Growth and financing, sleeve percentile 32.5					
Revenue growth, three-year compound	(6.4%)	10.1%	82.4	411	2025-12-31
Free cash flow growth, three-year compound	not computable	11.0%			
four consecutive annual FCF observations are required; found 2					
Reinvestment rate	not computable	37.1%			
pretax income must exceed the validity floor and imply a 0%-100% tax rate					
Asset growth, three years	106.5%	2.3%	1.9	693	2025-12-31
Net share issuance, one year	0.05%	2.4%	13.3	627	2026-03-17

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Late filer	found 1 NT 10-K/Q filings in the last eight quarters

Among 367 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
100	Travere Therapeutics, Inc. (TVTX)	27.0	B	
101	Tela Bio, Inc. (TELA)	27.3	B	fortress balance sheet
102	Alphatec Holdings, Inc. (ATEC)	27.6	B	
103	NeuroPace Inc. (NPCE)	27.9	B	
104	Myriad Genetics Inc. (MYGN)	28.1	B	fortress balance sheet
105	Agape ATP Corp. (ATPC)	28.4	B	late filer
106	Healthcare Services Group Inc. (HCSG)	28.7	B	
107	Tandem Diabetes Care Inc. (TNDM)	29.0	B	
108	Agios Pharmaceuticals, Inc. (AGIO)	29.2	B	short runway
109	Cadre Holdings, Inc. (CDRE)	29.5	B	
110	Cytokinetics Inc. (CYTK)	29.8	B	short runway

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-11-12 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(96.6%)	(1.5%)	0
Distance from 52-week high	(98.2%)	(32.0%)	0
EBIT to enterprise value	not computable	(1.8%)	
Free cash flow yield	(66.9%)	(1.0%)	11
Book value to price	17.35	0.29	99
Sales to price	1.20	0.29	84
Composite equity issuance, five years	not computable	19.1%	
Relative strength against the sector, log excess return	(3.54)	(0.18)	0

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$45,480
Operating cash flow, four quarters	-$970,178
Months of runway	not finite
Days since last periodic filing	93 (10-Q received Aug 14, 2026)
Median daily dollar volume, 63 sessions	$27,646

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$838,270	2025-12-31	2026-04-13	10-K	26-016297
2	assets	us-gaap:Assets	$24.6M	2025-12-31	2026-04-13	10-K	26-016297
3	net income	us-gaap:NetIncomeLoss	-$2.3M	2025-12-31	2026-04-13	10-K	26-016297
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$2.4M	2025-12-31	2026-04-13	10-K	26-016297
5	assets	us-gaap:Assets	$3.2M	2024-12-31	2026-04-13	10-K	26-016297
6	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.5M	2025-12-31	2026-04-13	10-K	26-016297
7	gross profit	us-gaap:GrossProfit	$759,148	2024-12-31	2026-04-13	10-K	26-016297
8	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.3M	2024-12-31	2026-04-13	10-K	26-016297
9	gross profit	us-gaap:GrossProfit	$936,572	2023-12-31	2025-03-31	10-K	25-001611
10	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.4M	2023-12-31	2025-03-31	10-K	25-001611
11	gross profit	us-gaap:GrossProfit	$1.2M	2022-12-31	2024-04-01	10-K	24-012467
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.9M	2022-12-31	2024-04-01	10-K	24-012467
13	gross profit	us-gaap:GrossProfit	$719,629	2021-12-31	2023-03-31	10-K	23-010029
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.0M	2021-12-31	2023-03-31	10-K	23-010029
15	current assets	us-gaap:AssetsCurrent	$24.3M	2025-12-31	2026-04-13	10-K	26-016297
16	current liabilities	us-gaap:LiabilitiesCurrent	$2.1M	2025-12-31	2026-04-13	10-K	26-016297
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$11.8M	2025-12-31	2026-04-13	10-K	26-016297
18	operating income	us-gaap:OperatingIncomeLoss	-$3.3M	2025-12-31	2026-04-13	10-K	26-016297

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	book equity	us-gaap:StockholdersEquity	$22.5M	2025-12-31	2026-04-13	10-K	26-016297
20	liabilities	us-gaap:Liabilities	$2.2M	2025-12-31	2026-04-13	10-K	26-016297
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$3,959	2021-12-31	2022-07-05	10-K/A	22-018503
22	depreciation amortization	us-gaap:Depreciation	$75,797	2021-12-31	2023-03-31	10-K	23-010029
23	operating income	us-gaap:OperatingIncomeLoss	-$1.9M	2021-12-31	2023-03-31	10-K	23-010029
24	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$2.4M	2021-12-31	2023-03-31	10-K	23-010029
25	income tax	us-gaap:IncomeTaxExpenseBenefit	$137,067	2021-12-31	2023-03-31	10-K	23-010029
26	current assets	us-gaap:AssetsCurrent	$3.9M	2021-12-31	2023-03-31	10-K	23-010029
27	current liabilities	us-gaap:LiabilitiesCurrent	$1.3M	2021-12-31	2023-03-31	10-K	23-010029
28	current assets	us-gaap:AssetsCurrent	$5.7M	2020-12-31	2022-07-05	10-K/A	22-018503
29	current liabilities	us-gaap:LiabilitiesCurrent	$1.0M	2020-12-31	2022-07-05	10-K/A	22-018503
30	assets	us-gaap:Assets	$5.7M	2023-12-31	2025-03-31	10-K	25-001611
31	assets	us-gaap:Assets	$2.8M	2022-12-31	2024-04-01	10-K	24-012467
32	shares outstanding	dei:EntityCommonStockSharesOutstanding	1,000,626	2026-03-17	2026-04-13	10-K	26-016297
33	shares outstanding	dei:EntityCommonStockSharesOutstanding	50,005,381	2025-03-28	2025-03-31	10-K	25-001611

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.